Deciphera Pharmaceuticals, Llc

This study tests a drug called vimseltinib in people with a rare joint tumor (tenosynovial giant cell tumor, or TGCT) and advanced solid tumors. The drug blocks a protein that helps these tumors grow. The trial has two phases: first, finding the safest dose, then expanding to see…

This phase 3 trial tests vimseltinib, an oral drug, for tenosynovial giant cell tumor (TGCT) when surgery isn't possible. About 123 adults with symptomatic TGCT will receive either vimseltinib or a placebo for 24 weeks, then all can get the drug. The main goal is to see if the dr…

This phase 3 trial compares two targeted cancer pills, ripretinib and sunitinib, in about 450 people with advanced gastrointestinal stromal tumor (GIST) whose first treatment (imatinib) stopped working or caused side effects. The main goal is to see if ripretinib delays cancer gr…

This study compares two drugs, ripretinib and sunitinib, in people with advanced gastrointestinal stromal tumors (GIST) that have specific genetic changes (KIT exon 11 plus 17/18 mutations) and have stopped responding to the first treatment, imatinib. About 54 participants will b…